Lead Product(s): Olinvacimab,Immunotherapy
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase II Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2020
Binex is responsible for large-scale manufacturing of clinical investigational material for PharmAbcine for its global Phase 2 trials on olinvacimab + immunotherapy combination for metastatic triple negative breast cancer and trials on various common solid tumors.